# Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

> **NCT07497607** · PHASE2 · RECRUITING · sponsor: **Sara Medek** · enrollment: 31 (estimated)

## Conditions studied

- Oropharyngeal Squamous Cell Carcinoma
- HPV Positive Oropharyngeal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT07497607
- **Lead sponsor:** Sara Medek
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-13
- **Primary completion:** 2031-05-13
- **Final completion:** 2036-05-13
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07497607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07497607, "Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07497607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*